...
机译:可切除性胰腺癌新辅助化疗的随机2期试验:吉西他滨与吉西他滨联合顺铂联合治疗
Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit University of Birmingham Vincent Drive Birmingham B15 2TT United Kingdom;
Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit University of Birmingham Vincent Drive Birmingham B15 2TT United Kingdom;
Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit University of Birmingham Vincent Drive Birmingham B15 2TT United Kingdom;
The Liver Unit Queen Elizabeth Hospital Birmingham B15 2TH United Kingdom;
Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit University of Birmingham Vincent Drive Birmingham B15 2TT United Kingdom;
Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit University of Birmingham Vincent Drive Birmingham B15 2TT United Kingdom;
The Liver Unit Queen Elizabeth Hospital Birmingham B15 2TH United Kingdom;
The Liver Unit Queen Elizabeth Hospital Birmingham B15 2TH United Kingdom;
Neoadjuvant chemotherapy; Pancreatic cancer; Randomized phase 2 trial; Gemcitabine; Cisplatin;
机译:在可切除的胰腺癌中新辅助化疗的随机2期试验:单独吉西他滨与吉西他滨联合顺铂的比较。
机译:Neoadjuvant Folfirinox总基于Neoadjuvant Gemcitabine的化学疗法和佐剂吉西他滨,用于可切除和边界可重型的胰腺癌(Preopanc-2试验):用于全国多中心随机对照试验的研究方案
机译:随机阶段II / III试验Neoadjuvant化疗与吉西他滨和S-1与前期手术进行可重置胰腺癌(Prep-02 / JSAP05)
机译:Gemcitabine +顺铂组合电化学疗法三重阴性乳腺癌:体外模型研究
机译:吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
机译:Neoadjuvant Folfirinox总基于Neoadjuvant Gemcitabine的化学疗法和佐剂吉西他滨用于可重症和边界可重置胰腺癌(Preopanc-2试验):用于全国多中心随机对照试验的研究方案
机译:一项II期随机临床试验,评估了在接受两个疗程的顺铂-吉西他滨,紫杉醇-吉西他滨对化疗双重治疗的早期改良与继续进行顺铂-吉西他滨化疗之后的稳定疾病的晚期非小细胞肺癌患者(GFPC 03-01研究)。